207 related articles for article (PubMed ID: 8194882)
1. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Kobayashi H; Gotoh J; Fujie M; Shinohara H; Moniwa N; Terao T
Int J Cancer; 1994 Jun; 57(5):727-33. PubMed ID: 8194882
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models.
Kobayashi H; Shinohara H; Fujie M; Gotoh J; Itoh M; Takeuchi K; Terao T
Int J Cancer; 1995 Nov; 63(3):455-62. PubMed ID: 7591248
[TBL] [Abstract][Full Text] [Related]
4. Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Kobayashi H; Fukuda Y; Yoshida R; Kanada Y; Nishiyama S; Suzuki M; Kanayama N; Terao T
Int J Cancer; 2004 Nov; 112(3):519-24. PubMed ID: 15382080
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
6. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
7. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
8. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
9. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
[TBL] [Abstract][Full Text] [Related]
10. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
[TBL] [Abstract][Full Text] [Related]
11. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.
Datta A; Kitson RP; Xue Y; al-Atrash G; Mazar AP; Jones TR; Goldfarb RH
In Vivo; 2002; 16(6):451-7. PubMed ID: 12494889
[TBL] [Abstract][Full Text] [Related]
12. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
13. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain.
Stepanova V; Bobik A; Bibilashvily R; Belogurov A; Rybalkin I; Domogatsky S; Little PJ; Goncharova E; Tkachuk V
FEBS Lett; 1997 Sep; 414(2):471-4. PubMed ID: 9315743
[TBL] [Abstract][Full Text] [Related]
14. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
15. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Guo Y; Higazi AA; Arakelian A; Sachais BS; Cines D; Goldfarb RH; Jones TR; Kwaan H; Mazar AP; Rabbani SA
FASEB J; 2000 Jul; 14(10):1400-10. PubMed ID: 10877833
[TBL] [Abstract][Full Text] [Related]
16. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
Yu HR; Schultz RM
Cancer Res; 1990 Dec; 50(23):7623-33. PubMed ID: 1701350
[TBL] [Abstract][Full Text] [Related]
17. Prevention of metastasis by inhibition of the urokinase receptor.
Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Liu G; Shuman MA; Cohen RL
Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
[TBL] [Abstract][Full Text] [Related]
19. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511
[TBL] [Abstract][Full Text] [Related]
20. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
